National Institute of Biological Sciences, NIBS, Beijing 102206, China.
J Genet Genomics. 2010 Jul;37(7):415-21. doi: 10.1016/S1673-8527(09)60060-6.
Embryonic stem cells (ESCs) derived from the early embryos possess two important characteristics: self-renewal and pluripotency, which make ESCs ideal seed cells that could be potentially utilized for curing a number of degenerative and genetic diseases clinically. However, ethical concerns and immune rejection after cell transplantation limited the clinical application of ESCs. Fortunately, the recent advances in induced pluripotent stem cell (iPSC) research have clearly shown that differentiated somatic cells from various species could be reprogrammed into pluripotent state by ectopically expressing a combination of several transcription factors, which are highly enriched in ESCs. This ground-breaking achievement could circumvent most of the limitations that ESCs faced. However, it remains challenging if the iPS cell lines, especially the human iPSCs lines, available are fully pluripotent. Therefore, it is prerequisite to establish a molecular standard to distinguish the better quality iPSCs from the inferior ones.
胚胎干细胞(ESCs)来源于早期胚胎,具有自我更新和多能性这两个重要特征,使其成为理想的种子细胞,有潜力用于临床治疗多种退行性和遗传性疾病。然而,细胞移植后的伦理问题和免疫排斥反应限制了 ESCs 的临床应用。幸运的是,诱导多能干细胞(iPSC)研究的最新进展清楚地表明,来自不同物种的分化体细胞可以通过异位表达几种转录因子组合重编程为多能状态,这些转录因子在 ESCs 中高度富集。这一突破性的成就可以规避 ESCs 面临的大多数限制。然而,如果现有的 iPS 细胞系,特别是人类 iPSCs 系,是否完全具有多能性,仍然具有挑战性。因此,建立一个分子标准来区分高质量的 iPSCs 和低质量的 iPSCs 是前提条件。